Four senior FDA leaders forged close ties with Biogen well ahead of Aduhelm's approval. Now they've left FDA
Two years after the FDA’s controversial approval of Biogen’s Alzheimer’s drug Aduhelm, four of the top agency officials who came under scrutiny for their close relationship with the drugmaker during the approval process have left the agency.
Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers. The landing spot for the fourth — Billy Dunn, former director of the Division of Neurology Products — has yet to be made public.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.